Cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs) are toll-like receptor 9 (TLR9) agonists, and CpG ODNs are often used as anti-tumor adjuvants in clinical trials. This evidence concerns the gene TLR9 and neoplasm.